tbuckley/cabot-search huggingface dataset:
Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia
Authors: Jorge J. Castillo, Joshua N. Gustine, Andrew Keezer, Kirsten Meid, Catherine A. Flynn, Toni E. Dubeau, Gloria Chan, Jiaji Chen, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
Journal: American Journal of Hematology (2019)

Rituximab-containing regimens are commonly used for frontline therapy in patients with symptomatic Waldenström macroglobulinemia (WM). We had observed that a portion of WM patients experienced deepening of response months to years after therapy completion. We carried a retrospective study aimed at describing this phenomenon. We gathered baseline data, and responses at end of induction, end of maintenance and best response. Deepening of response was defined as ≥25% decrease in serum IgM achieved at a later time from therapy completion. Of 178 patients included, 116 (65%) received maintenance therapy and 62 (35%) were observed. In patients who received maintenance, 44 (38%) had ≥25% decrease in serum IgM level after the end of maintenance with a median time from end of maintenance to lowest IgM level of 1.6 years (range 0.1-7.9 years). In patients who were observed, 19 (31%) had ≥25% decrease in serum IgM level after the end of induction with a median time from end of induction to lowest IgM level of 1.6 years (range 0.2-5.1 years). Baseline hemoglobin <11.5 g/dL, bone marrow involvement ≥50%, CXCR4 mutations and serum IgM ≥4000 mg/dL were associated with lower odds of deepening of response after therapy completion. Deepening of response was associated with better progression-free survival (PFS; HR 0.46, 95% CI 0.26-0.80; P = .006) and better survival after frontline treatment initiation (SAFTI; HR 0.21, 95% CI 0.06-0.73; P = .01). In conclusion, deepening of response occurs in one third of WM patients after completing rituximab-containing regimens and was associated with better PFS and SAFTI.
Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults
Authors: Rachel H. Alinsky, Bonnie T. Zima, Jonathan Rodean, Pamela A. Matson, Marc R. Larochelle, Hoover Adger, Sarah M. Bagley, Scott E. Hadland
Journal: JAMA Pediatrics (2020)

Nonfatal opioid overdose may be a critical touch point when youths who have never received a diagnosis of opioid use disorder can be engaged in treatment. However, the extent to which youths (adolescents and young adults) receive timely evidence-based treatment following opioid overdose is unknown.
Evaluating risk of hospitalization with G-CSF use in real-world oncology practice
Authors: H. Tan, K. Tomic, G. Daniel, D. Hurley, R. Barron
Journal: Journal of Clinical Oncology (2009)

6626 Background: Limited published data exist on how granulocyte colony-stimulating factor (G-CSF) treatment patterns affect risk of neutropenia-related hospitalizations. This study examines prophylactic vs. delayed use of G-CSF and compares the effectiveness of prophylaxis with filgrastim (FIL) vs. pegfilgrastim (PEG). Methods: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008. For these patients, the first course of chemotherapy and each unique cycle with use of G-CSF (FIL or PEG) was identified and designated ‘prophylaxis’ if used within the first 5 days of each cycle, or ‘delayed', if after day 5. The risk of neutropenia-related hospitalization was then evaluated on a cycle basis. A generalized estimating equation (GEE) was used to adjust for baseline demographics and clinical characteristics. Results: Among 5,571 patient-cycles identified: 87.4% were prophylactic and 12.6% were delayed G-CSF. PEG use was primarily prophylactic (93.6%) in contrast to use of FIL which was delayed in 62.5% of patient-cycles. The rate of neutropenic hospitalization was 1.2% for prophylaxis (n=59) and 3.7% for delayed G-CSF (n=26) (P &lt; 0.001). Among prophylactic patient-cycles, the neutropenic hospitalization rate was lower with PEG than FIL (1.1% (n=51) vs. 3.5% (n=8), p = 0.001). Multivariate analyses using GEE model showed consistent trends (Table). Conclusions: Prophylactic G-CSF use was associated with lower neutropenic hospitalization risk than delayed use. Among prophylactic use in real-world oncology practice, PEG was associated with about a two-thirds lower risk of neutropenic hospitalization compared with FIL. [Table: see text] [Table: see text]
Host factors associated to false negative and indeterminate results in an interferon‐γ release assay in patients with active tuberculosis
Authors: J.A. Santos, R. Duarte, C. Nunes
Journal: Pulmonology (2019)

Information on host factors that contribute to false negative and indeterminate results in interferon-γ release assays (IGRA) are critical to improve the usefulness of these tests in the fight against tuberculosis (TB) epidemics. The aim of this study was to estimate and compare the sensitivity of an IGRA and the tuberculin skin test (TST), independently and as a combined approach, in patients with TB and to identify risk factors associated with false negative and indeterminate IGRA results.Retrospective cohort study of all active TB notifications with an IGRA result (n = 1230), from 2008 to 2015. 68.0 % (n = 727) of these patients had a TST result interpreted using a 5 mm (TST-5 mm) and 10 mm (TST-10 mm) cutoff. Sensitivity was determined for both tests. Logistic regression analysis was used to evaluate the association of sociodemographic and clinical factors to the risk of false negative or indeterminate IGRA results.IGRA, TST-5 mm and TST-10 mm were positive in 82.4 %, 84.5 % and 78.4 % of the patients that performed both tests. When used combined, IGRA/TST-5 mm sensitivity was 91.7 % and IGRA/TST-10 mm sensitivity was 90.6 %. Age≥65 years, alcohol abuse and pulmonary TB were predictive factors for indeterminate results. Inflammatory diseases and pulmonary TB were statistically associated with false negative IGRA results.Inflammatory diseases and pulmonary TB were identified as factors for false negative IGRA results. Our results indicate that the use of both tests in a combined approach, especially in specific risk groups of the population, could increase the sensitivity of the screening process and accelerate the achievement of the WHO End TB Strategy goals.
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older—Reply
Authors: Richard G. Bach, Christopher P. Cannon, Michael A. Blazing
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment
Authors: Yelei Guo, Kaichao Feng, Chuan Tong, Hejin Jia, Yang Liu, Yao Wang, Dongdong Ti, Qingming Yang, Zhiqiang Wu, Weidong Han
Journal: Cellular and Molecular Immunology (2020)
PTPRε Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF‐β Receptor 1
Authors: Zhibin Liao, Lin Chen, Xuewu Zhang, Hongwei Zhang, Xiaolong Tan, Keshuai Dong, Xun Lu, He Zhu, Qiumeng Liu, Zhanguo Zhang, Zeyang Ding, Wei Dong, Peng Zhu, Liang Chu, Huifang Liang, Pran K. Datta, Bixiang Zhang, Xiaoping Chen
Journal: Hepatology (2020)

Background and Aims Transforming growth factor beta (TGF‐β) suppresses early stages of tumorigenesis, but contributes to the migration and metastasis of cancer cells. However, the role of TGF‐β signaling in invasive prometastatic hepatocellular carcinoma (HCC) is poorly understood. In this study, we investigated the roles of canonical TGF‐β/mothers against decapentaplegic homolog 3 (SMAD3) signaling and identified downstream effectors on HCC migration and metastasis. Approach and Results By using in vitro trans‐well migration and invasion assays and in vivo metastasis models, we demonstrated that SMAD3 and protein tyrosine phosphatase receptor epsilon (PTPRε) promote migration, invasion, and metastasis of HCC cells in vitro and in vivo . Further mechanistic studies revealed that, following TGF‐β stimulation, SMAD3 binds directly to PTPRε promoters to activate its expression. PTPRε interacts with TGFBR1/SMAD3 and facilitates recruitment of SMAD3 to TGFBR1, resulting in a sustained SMAD3 activation status. The tyrosine phosphatase activity of PTPRε is important for binding with TGFBR1, recruitment and activation of SMAD3, and its prometastatic role in vitro . A positive correlation between pSMAD3/SMAD3 and PTPRε expression was determined in HCC samples, and high expression of SMAD3 or PTPRε was associated with poor prognosis of patients with HCC. Conclusions PTPRε positive feedback regulates TGF‐β/SMAD3 signaling to promote HCC metastasis.
CD93-Signaling Regulates Self-Renewal and Proliferation of Chronic Myeloid Leukemia Stem Cells in Mice and Humans and Might be a Promising Target for Treatment
Authors: Carsten Riether, Ramin Radpour, Chantal L. Bachmann, Christian M Schürch, Miroslav Arambasic, Gabriela M Baerlocher, Adrian F Ochsenbein
Journal: Blood (2019)
P2.08-01 Outcomes Following Gamma Knife Radiosurgery for Oligometastatic Brain Metastases in Patients with NSCLC at Leeds Cancer Centre
Authors: R. Samuel, O. Coen, G. Higginbotham, G. Wright, P. Hatfield, K. Franks, P. Jain, M. Snee, K. Clarke
Journal: Journal of Thoracic Oncology (2019)
Nanocarrier-mediated antioxidant delivery for liver diseases
Authors: Senlin Li, Huiru Li, Xiaoding Xu, Phei Er Saw, Lei Zhang
Journal: Theranostics (2020)

Liver is the principal detoxifying organ and metabolizes various compounds that produce free radicals (FR) constantly.To maintain the oxidative/antioxidative balance in the liver, antioxidants would scavenge FR by preventing tissue damage through FR formation, scavenging, or by enhancing their decomposition.The disruption of this balance therefore leads to oxidative stress and in turn leads to the onset of various diseases.Supplying the liver with exogeneous antioxidants is an effective way to recreate the oxidative/antioxidative balance in the liver homeostasis.Nevertheless, due to the short half-life and instability of antioxidants in circulation, the methodology for delivering antioxidants to the liver needs to be improved.Nanocarrier mediated delivery of antioxidants proved to be an ingenious way to safely and efficiently deliver a high payload of antioxidants into the liver for circumventing liver diseases.The objective of this review is to provide an overview of the role of reactive oxygen species (oxidant) and ROS scavengers (antioxidant) in liver diseases.Subsequently, current nanocarrier mediated antioxidant delivery methods for liver diseases are discussed.
Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa
Authors: Peter Olupot-Olupot, George A. Tomlinson, Teresa S. Latham, Patrick T. McGann, Brigida Santos, Banu Aygun, Susan Stuber, Leon Tshilolo, Adam Lane, Thomas N. Williams, Russell E. Ware
Journal: Blood (2019)
Silica Exposure and Scleroderma: More Bridges and Collaboration between Disciplines Are Needed
Authors: Alain Lescoat, Catherine Cavalin, Alice Ballerie, Valérie Lecureur, Lucile Sesé, Claire Cazalets, Mathieu Lederlin, Guillaume Coiffier, Nicolas Belhomme, Christophe Paris, Ronan Garlantézec, Stéphane Jouneau, Patrick Jégo
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Hospital characteristics and breast cancer patients’ evaluation of care.
Authors: Holger Pfaff, Christoph Kowalski, Lena Ansmann, Julia Ingendahl
Journal: Journal of Clinical Oncology (2013)

e17550 Background: There is a large body of research on patient evaluations of care and its associations with patient characteristics, such as the sociodemographics or the severity of diseases. A number of studies have recently been published that consider the characteristics of various hospitals in order to explain the differences in patient evaluations between hospitals in non-oncological patient populations. This study investigates the relationship between13 dimensions of satisfaction and breast center hospital characteristics which account for the patient case mix. Methods: The cross-sectional survey data of 3,601 newly-diagnosed breast cancer patients (response rate: 88% of consenting patients) who were treated in 85 out of 91 breast center hospitals in the German state of North Rhine-Westphalia in 2010 were combined with structural data from a key informant survey from the same hospitals. Multilevel linear regression models were calculated in order to investigate patients’ evaluations of the care differences between hospitals and their associations with hospital characteristics (i.e. teaching status, volume, network size, clinical studies, case manager employed) accounting for patient characteristics (self-rated health, mother language, insurance status, age, education, cancer stage, type of surgery). Results: Patients evaluated non-teaching hospitals as being statistically significantly better in 8 out of 13 satisfaction dimensions. None of the other hospital characteristics were significantly associated with any of the satisfaction dimensions. Overall, the differences between hospitals were small to moderate, with null model ICCs ranging from 0.02 to 0.09 for the different dimensions. Conclusions: Teaching breast cancer hospitals face substantial difficulties in achieving patient evaluations that are as good as those from non-teaching hospitals in Germany. The question of extra staffing for the additional teaching tasks needs to be discussed.
Abstract 225: Cytotoxic extracts of ethnomedicinal plants <i>Podophyllum</i> <i>peltatum</i> (Mayapple) and <i>Echinacea angustifolia</i>
Authors: Olena T. McDowell, Elbert L. Myles
Journal: Cancer Research (2010)

Abstract Phytochemicals and other natural compounds are historically established as cures for many ailments in rural America and developing countries. Our lab is testing plants that show potential for inhibiting the growth of cancer cells. The family Asteraceae and the family Berberidacae are very well known for there values as medicinal plants. More specifically, the genus species Echinacea angustifolia and genus species Podophyllum peltatum commonly known as the Mayapple, both are noted for there unique medicinal purposes. The crude methanolic extracts of these plants were tested against human metastatic cell lines representing breast (MCF-7),(BT-549), and (BT-20) tissues. Trypan blue exclusion is used to determine viable cell counts. Alamar BlueTM and florescent analysis were used to evaluate the cytoxicity of the extracts. Analysis of the crude extracts of Echinacea angustifolia has shown on MCF-7, BT-549 and BT-20 that most of them exhibit anticancer activity against the cell lines at the maximum concentration of 200 g /mL. In particular, less diluted concentrations have demonstrated exceptional inhibitory effects with IC50 values ranging between 0.10-15 g /mL, respectively. On the other hand, analysis of the crude extracts of Podophyllum peltatum (Mayapple) has shown on MCF-7, and BT-549 some anticancer activity against cell lines at the maximum concentration of 200 g /mL. More specifically, the more diluted concentrations have demonstrated exceptional growth inhibition with IC50 values ranging between 2-8g /mL Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 225.
The subjective experience of recollection and familiarity in Alzheimer's disease
Authors: Dimitrios Kapogiannis, Mohamad El Haj
Journal: Behavioral and Brain Sciences (2019)

Abstract Although the integrative memory model proposed by Bastin et al. is interesting, particularly for Alzheimer's disease, it may benefit from incorporating the subjective experience of recollection. We therefore offer complementary lines of interpretation to explain how recollection and familiarity in Alzheimer's disease can be dissociated based not only on accounts of their neural correlates but, critically, on the subjective experience of memory in patients.
Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper
Authors: Abderrahim Oussalah, Vincent Yip, Cristobalina Mayorga, Miguel Blanca, Annick Barbaud, Alla Nakonechna, Josefina Cernadas, Maia Gotua, Knut Brockow, Jean‐Christoph Caubet, Andreas Bircher, Marina Atanaskovic‐Markovic, Pascal Demoly, Luciana Kase‐Tanno, Ingrid Terreehorst, José Julio Laguna, Antonino Romano, Jean‐Louis Guéant, Munir Pirmohamed
Journal: Allergy (2020)

Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell-mediated reactions classically occur more than 6 hours after drug administration and include life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA-compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future.
Abstract 15881: Effect Modification of Neighborhood Greenness on the Relationship Between Ambient Air Pollution and Arterial Stiffness
Authors: Daniel W Riggs, Daniel J Conklin, Ray Yeager, Natasha DeJarnett, Rachel J Keith, Andrew P DeFilippis, Shesh N Rai, Aruni Bhatnagar
Journal: Circulation (2019)

Introduction: Exposure to air pollution has been linked to excessive CVD risk and mortality. Recent evidence also suggests that living in greener areas is associated with reduced CVD risk, however,...
Nonindigenous East/Central/South African genotype of chikungunya virus identified in febrile returning travellers in Yunnan, China
Authors: Yue Feng, Hui Xiao, Xiaofei Li, Yunlan Lu, Jie Li, Mengyuan Zheng, Dongbiao Lv, Wei Yuan, Ziyang Zhang, Yan Zhou, Yuebo Liang, Weihong Qin, Xueshan Xia
Journal: Journal of Infection (2019)
Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Yiming Tu, Zhenyao Chen, Pengzhan Zhao, Guangchi Sun, Zhongyuan Bao, Honglu Chao, Liang Fan, Chong Li, Yongping You, Yan Qu, Yun Chen, Jing Ji
Journal: Clinical Cancer Research (2020)

Glioblastoma (GBM) is one of the most aggressive and lethal cancer types in humans. The standard treatment approach is surgery followed by chemoradiation. However, the molecular mechanisms of innate tumor radioresistance remain poorly understood.We tested the expression of Smoothened (Smo) in primary and recurrent GBM tissues and cells. Then, we determined radiation effectiveness against primary and recurrent GBM cells. Lastly, the functional role of Smo in GBM radioresistance was further confirmed by in vitro and in vivo experiments.We reported that Smo was significantly upregulated in recurrent GBM cell lines and tumor tissues following radiation treatment. Higher Smo expression indicated poor prognosis of GBM patients after radiation treatment. Smo had radioresistance effects in both GBM cells and human tumor xenografts. The mechanisms underlying these effects involved the attenuation of DNA damage repair caused by IR. Importantly, we found that the effect of Smo on radioresistance was mediated by Claspin polyubiquitination and proteasomal degradation, leading to the regulation of ATR-Chk1 signaling. Moreover, we found that Smo reduced Claspin polyubiquitination and proteasomal degradation by promoting USP3 transcription. Furthermore, we demonstrated that the Smo inhibitor GDC-0449 induced radiosensitivity to GBM.These data suggest that Smo confers radiation resistance in GBM by promoting USP3 transcription, leading to the activation of Claspin-dependent ATR-Chk1 signaling. These findings identify a potential mechanism of GBM resistance to radiation and suggest a potential therapeutic target for radiation resistance in GBM.
Abstract 11170: Trends in Initiation of Antihypertensive Medication With Combination Therapy in a US Integrated Healthcare System
Authors: Jaejin An, Kristi Reynolds, Rong Wei, Tiffany Luong, Lei Qian, Jeff Brettler, Marc Jaffe, Paul Muntner
Journal: Circulation (2019)

Initiation of antihypertensive medication with combination therapy is recommended for many patients with hypertension to shorten the time needed to reach blood pressure [BP] goals. We examined tren...